{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T05:20:06Z","timestamp":1781328006076,"version":"3.54.1"},"reference-count":125,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1097\/mcg.0b013e3182333820","type":"journal-article","created":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T14:23:58Z","timestamp":1325859838000},"page":"93-114","source":"Crossref","is-referenced-by-count":68,"title":["Recent Safety Concerns With Proton Pump Inhibitors"],"prefix":"10.1097","volume":"46","author":[{"given":"Joan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong Cathy","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grigorios I.","family":"Leontiadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin W.","family":"Howden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-4-20210305","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jacc.2007.06.064","article-title":"Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study.","volume":"51","author":"Gilard","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R2-4-20210305","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.jacc.2008.05.053","article-title":"Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors.","volume":"52","author":"Pezalla","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R3-4-20210305","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1503\/cmaj.082001","article-title":"A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.","volume":"180","author":"Juurlink","year":"2009","journal-title":"CMAJ"},{"key":"R4-4-20210305","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jama.2009.261","article-title":"Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome.","volume":"301","author":"Ho","year":"2009","journal-title":"JAMA"},{"key":"R5-4-20210305","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1592\/phco.30.8.787","article-title":"Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel MEDCO outcomes study.","volume":"30","author":"Kreutz","year":"2010","journal-title":"Pharmacotherapy"},{"key":"R6-4-20210305","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0140-6736(09)61525-7","article-title":"Pharmacodynamic effect and clinical efficacy of clopidogrel and plasugrel with or without a proton pump inhibitor: an analysis of two randomized trials.","volume":"374","author":"ODonoghue","year":"2009","journal-title":"Lancet"},{"key":"R7-4-20210305","doi-asserted-by":"crossref","first-page":"337","DOI":"10.7326\/0003-4819-152-6-201003160-00003","article-title":"Outcomes with concurrent use of clopidogrel and proton-pump inhibitors: a cohort study.","volume":"152","author":"Ray","year":"2010","journal-title":"Ann Intern Med"},{"key":"R8-4-20210305","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1038\/ajg.2010.326","article-title":"PPIs and clopidogrel: the band plays on.","volume":"105","author":"Howden","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"R9-4-20210305","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1111\/j.1572-0241.2008.02216.x","article-title":"ACCFACGAHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use.","volume":"103","author":"Bhatt","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"R10-4-20210305","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1038\/ajg.2010.445","article-title":"ACCFACGAHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCFACGAHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use.","volume":"105","author":"Abraham","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"R11-4-20210305","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel.","volume":"360","author":"Mega","year":"2009","journal-title":"N Engl J Med"},{"key":"R12-4-20210305","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1080\/003655200750023705","article-title":"Gastroduodenal tolerance of 75 mg clopidogrel versus 325 mg aspirin in healthy volunteers: a gastroscopic study.","volume":"35","author":"Fork","year":"2000","journal-title":"Scand J Gastroenterol"},{"key":"R15-4-20210305","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1136\/gut.2005.080754","article-title":"Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional nonaspirin non-steroidal anti-inflammatory drugs, aspirin and combinations.","volume":"55","author":"Lanas","year":"2006","journal-title":"Gut"},{"key":"R16-4-20210305","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2036.2006.02759.x","article-title":"Upper gastrointestinal bleeding associated with antiplatelet drugs.","volume":"23","author":"Ibanez","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"R17-4-20210305","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST segment elevation.","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"R18-4-20210305","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMoa0901301","article-title":"Effect of clopidogrel added to aspirin in patients with atrial fibrillation.","volume":"360","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"R19-4-20210305","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1517\/17425255.2010.519334","article-title":"A comparison of the metabolism of clopidogrel and prasugrel.","volume":"6","author":"Laizure","year":"2010","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R20-4-20210305","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1124\/dmd.109.029132","article-title":"Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.","volume":"38","author":"Kazui","year":"2010","journal-title":"Drug Metab Dispo"},{"key":"R22-4-20210305","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/clpt.2010.219","article-title":"Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies.","volume":"89","author":"Angiolillo","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"R23-4-20210305","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1185\/03007990802693883","article-title":"Pharmacokinetics and pharmacodynamics of a known active PPI with a novel dual delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials.","volume":"25","author":"Vakily","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"R24-4-20210305","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/dmd.32.8.821","article-title":"Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.","volume":"32","author":"Li","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"R25-4-20210305","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2165\/11531320-000000000-00000","article-title":"Drug-drug interaction profiles of proton pump inhibitors.","volume":"49","author":"Ogawa","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"R26-4-20210305","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1161\/CIRCULATIONAHA.109.907295","article-title":"Proton pump inhibitors and clopidogrel: putting the interaction in perspective.","volume":"120","author":"Juurlink","year":"2009","journal-title":"Circulation"},{"key":"R27-4-20210305","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1001\/jama.2010.1543","article-title":"Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.","volume":"304","author":"Mega","year":"2010","journal-title":"JAMA"},{"key":"R28-4-20210305","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jacc.2009.12.071","article-title":"Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C192 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis.","volume":"56","author":"Hulot","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R29-4-20210305","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jama.2009.1232","article-title":"Association of cytochrome P450 2C19 genotype with the antiplateleteffect and clinical efficacy of clopidogrel therapy.","volume":"302","author":"Shuldiner","year":"2009","journal-title":"J Am Med Assoc"},{"key":"R31-4-20210305","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijcard.2011.01.091","article-title":"Separate dosing of clopidogrel and omeprazole may improve platelet inhibition on dual antiplatelet therapy.","volume":"149","author":"Chyrchel","year":"2011","journal-title":"Int J Cardiol"},{"key":"R32-4-20210305","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jacc.2009.05.050","article-title":"Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study.","volume":"54","author":"Cuisset","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"R33-4-20210305","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1161\/CIRCINTERVENTIONS.110.957829","article-title":"Pharmacodynamic effects of concomitant versus staggered clopidogrel and omeprazole intake: results of a prospective randomized crossover study.","volume":"3","author":"Ferreiro","year":"2010","journal-title":"Circ Cardiovasc Interv"},{"issue":"Suppl III","key":"R34-4-20210305","first-page":"A2","article-title":"The clopidogrel-proton pump inhibitors drug interaction is not a class effect: a randomized clinical study in patients after acute myocardial infarction under dual anti-platelet therapy abstract OP006.","volume":"59","author":"Fontes-Carvalho","year":"2010","journal-title":"Gut"},{"key":"R35-4-20210305","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1365-2125.2010.03717.x","article-title":"Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes.","volume":"70","author":"Furuta","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"R36-4-20210305","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1111\/j.1538-7836.2006.02162.x","article-title":"Influence of omeprazol on the antiplatelet action of clopidogrel associated to aspirin.","volume":"4","author":"Gilard","year":"2006","journal-title":"J Thromb Haemost"},{"key":"R37-4-20210305","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1097\/FJC.0b013e3181f68209","article-title":"The influence of proton pump inhibitors on the antiplatelet potency of clopidogrel evaluated by 5 different platelet function tests.","volume":"56","author":"Gremmel","year":"2010","journal-title":"J Cardiovasc Pharmacol"},{"key":"R40-4-20210305","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.1538-7836.2009.03729.x","article-title":"Effect of an increased clopidogrel maintenance dose or lansoprazole co-administration on the antiplatelet response to clopidogrel in CYP2C19-genotyped healthy subjects.","volume":"8","author":"Hulot","year":"2010","journal-title":"J Thromb Haemost"},{"key":"R41-4-20210305","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/FJC.0b013e3181e19739","article-title":"Pantoprazole does not influence the antiplatelet effect of clopidogrel-a whole blood aggregometry study after coronary stenting.","volume":"56","author":"Neubauer","year":"2010","journal-title":"Cardiovasc Pharmacol"},{"key":"R42-4-20210305","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1747-0803.2010.00461.x","article-title":"Platelet activity associated with concomitant use of clopidogrel and proton pump inhibitors in children with cardiovascular disease.","volume":"5","author":"Pasquali","year":"2010","journal-title":"Congenit Heart Dis"},{"key":"R43-4-20210305","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.amjcard.2009.01.341","article-title":"Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention.","volume":"103","author":"Price","year":"2009","journal-title":"Am J Cardiol"},{"key":"R44-4-20210305","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1160\/TH08-12-0808","article-title":"Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel.","volume":"101","author":"Sibbing","year":"2009","journal-title":"Thromb Haemost"},{"key":"R45-4-20210305","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.ahj.2008.09.017","article-title":"Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel.","volume":"157","author":"Siller-Matula","year":"2009","journal-title":"Am Heart J"},{"key":"R46-4-20210305","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1253\/circj.CJ-09-0913","article-title":"Comparison between the effect of omeprazole and rabeprazole on the antiplatelet action of clopidogrel.","volume":"74","author":"Siriswangvat","year":"2010","journal-title":"Circ J"},{"key":"R47-4-20210305","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1177\/0091270008315310","article-title":"Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.","volume":"48","author":"Small","year":"2008","journal-title":"J Clin Pharmacol"},{"key":"R48-4-20210305","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.jacc.2010.03.100","article-title":"Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.","volume":"56","author":"Storey","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R49-4-20210305","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1536\/ihj.51.13","article-title":"Effects of omeprazole on the antiplatelet activity of clopidogrel.","volume":"51","author":"Yun","year":"2010","journal-title":"Int Heart J"},{"key":"R50-4-20210305","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1177\/147323001003800506","article-title":"Differential effects of esomeprazole on the antiplatelet activity of clopidogrel in healthy individuals and patients after coronary stent implantation.","volume":"38","author":"Zhang","year":"2010","journal-title":"J Int Med Res"},{"key":"R51-4-20210305","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.thromres.2009.08.016","article-title":"Effect of comedication with proton pump inhibitors (PPIs) on post-interventional residual platelet aggregation in patients undergoing coronary stenting treated by dual antiplatelet therapy.","volume":"125","author":"Zuern","year":"2010","journal-title":"Thromb Res"},{"key":"R52-4-20210305","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.jacc.2006.11.044","article-title":"Variability in individual responsiveness to clopidogrel clinical implications, management, and future perspectives.","volume":"49","author":"Angiolillo","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R53-4-20210305","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1161\/01.CIR.0000130846.46168.03","article-title":"Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.","volume":"109","author":"Matetzky","year":"2004","journal-title":"Circulation"},{"key":"R54-4-20210305","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/j.1538-7836.2005.01751.x","article-title":"High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome.","volume":"4","author":"Cuisset","year":"2006","journal-title":"J Thromb Haemost"},{"key":"R55-4-20210305","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.jacc.2007.01.094","article-title":"Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis.","volume":"49","author":"Buonamici","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R56-4-20210305","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ccd.10497","article-title":"Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation.","volume":"59","author":"Barragan","year":"2003","journal-title":"Catheter Cardiovasc Interv"},{"key":"R57-4-20210305","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.amjcard.2010.10.073","article-title":"Effect of concomitant use of clopidogrel and proton pump inhibitors after percutaneous coronary intervention.","volume":"107","author":"Banerjee","year":"2011","journal-title":"Am J Cardiol"},{"key":"R58-4-20210305","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"Clopidogrel with or without omeprazole in coronary artery disease.","volume":"363","author":"Bhatt","year":"2010","journal-title":"N Engl J Med"},{"key":"R62-4-20210305","doi-asserted-by":"crossref","first-page":"S815","DOI":"10.1161\/circ.118.suppl_18.S_815-a","article-title":"Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial abstract 3999.","volume":"118","author":"Dunn","year":"2008","journal-title":"Circulation"},{"key":"R63-4-20210305","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/clc.20721","article-title":"Recurrence of acute myocardial infarction in patients discharged on clopidogrel and a proton pump inhibitor after stent placement for acute myocardial infarction.","volume":"33","author":"Evanchan","year":"2010","journal-title":"Clin Cardiol"},{"key":"R64-4-20210305","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.amjcard.2009.10.063","article-title":"Relation of proton pump inhibitor use after percutaneous coronary intervention with drug-eluting stents to outcomes.","volume":"105","author":"Gaglia","year":"2010","journal-title":"Am J Cardiol"},{"key":"R65-4-20210305","first-page":"1511","article-title":"Proton pump inhibitors in patients treated with aspirin and clopidogrel after acute coronary syndrome.","volume":"29","author":"Gaspar","year":"2010","journal-title":"Rev Port Cardiol"},{"key":"R66-4-20210305","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1007\/s10620-009-0960-8","article-title":"Risk of adverse clinical outcomes with concomitant use of clopidogrel and proton pump inhibitors following percutaneous coronary intervention.","volume":"55","author":"Gupta","year":"2010","journal-title":"Dig Dis Sci"},{"key":"R67-4-20210305","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.clinthera.2009.09.005","article-title":"A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding.","volume":"31","author":"Hsiao","year":"2009","journal-title":"Clin Ther"},{"key":"R68-4-20210305","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.amjcard.2010.01.348","article-title":"Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention.","volume":"105","author":"Huang","year":"2010","journal-title":"Am J Cardiol"},{"key":"R69-4-20210305","first-page":"257","article-title":"Effect of omeprazole on the concentration of interleukin-6 and transforming growth factor-1 in patients receiving dual antiplatelet therapy after percutaneous coronary intervention.","volume":"21","author":"Hudzik","year":"2010","journal-title":"Eur Cytokine Netw"},{"issue":"Suppl II","key":"R70-4-20210305","first-page":"A269","article-title":"GI cytoprotection after coronary stenting abstract P0824.","volume":"58","author":"Joshi","year":"2009","journal-title":"Gut"},{"key":"R71-4-20210305","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1161\/STROKEAHA.110.596643","article-title":"The safety of proton pump inhibitors and clopidogrel in patients after stroke.","volume":"42","author":"Juurlink","year":"2011","journal-title":"Stroke"},{"key":"R73-4-20210305","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1365-2710.2009.01089.x","article-title":"PPI use in patients commenced on clopidogrel: a retrospective cross-sectional evaluation.","volume":"35","author":"Luinstra","year":"2010","journal-title":"J Clin Pharm Ther"},{"key":"R74-4-20210305","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/FJC.0b013e3181fc65e5","article-title":"Concomitant use of proton pump inhibitors and clopidogrel in patients with coronary, cerebrovascular, or peripheral artery disease in the factores de riesgo y enfermedad arterial (FRENA) registry.","volume":"57","author":"Munoz-Torrero","year":"2011","journal-title":"J Cardiovasc Pharmacol"},{"key":"R75-4-20210305","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000141264","article-title":"Upper gastrointestinal bleeding in patients with aspirin and clopidogrel co-therapy.","volume":"77","author":"Ng","year":"2008","journal-title":"Digestion"},{"key":"R77-4-20210305","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1161\/CIRCULATIONAHA.109.873497","article-title":"Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome.","volume":"120","author":"Rassen","year":"2009","journal-title":"Circulation"},{"key":"R78-4-20210305","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/pds.1867","article-title":"Multivariate-adjusted pharmacoepidemiologic analyses of confidential information pooled from multiple health care utilization databases.","volume":"19","author":"Rassen","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R79-4-20210305","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/MCA.0b013e328343b03a","article-title":"Safety of clopidogrel and proton pump inhibitors in patients undergoing drug-eluting stent implantation.","volume":"22","author":"Rossini","year":"2011","journal-title":"Coron Artery Dis"},{"key":"R80-4-20210305","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1160\/TH09-11-0800","article-title":"Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors.","volume":"104","author":"Sarafoff","year":"2010","journal-title":"Thromb Haemost"},{"key":"R81-4-20210305","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1161\/CIRCULATIONAHA.110.965640","article-title":"Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry.","volume":"123","author":"Simon","year":"2011","journal-title":"Circulation"},{"key":"R82-4-20210305","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1001\/archinternmed.2010.34","article-title":"Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor.","volume":"170","author":"Stockl","year":"2010","journal-title":"Arch Intern Med"},{"key":"R83-4-20210305","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1160\/TH10-04-0218","article-title":"Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation.","volume":"104","author":"Tentzeris","year":"2010","journal-title":"Thromb Haemost"},{"key":"R84-4-20210305","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00535-010-0299-0","article-title":"Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding.","volume":"46","author":"Tsai","year":"2011","journal-title":"J Gastroenterol"},{"key":"R85-4-20210305","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-2036.2010.04485.x","article-title":"Risk of recurrent myocardial infarction with the concomitant use of clopidogrel and proton pump inhibitors.","volume":"33","author":"Valkhoff","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"R86-4-20210305","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1038\/ajg.2010.334","article-title":"Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch cohort study.","volume":"105","author":"van Boxel","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"R87-4-20210305","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1038\/ajg.2009.525","article-title":"Concomitant use of clopidogrel and proton pump inhibitors or cimetidine after acute myocardial infarction would increase the risk of re-infarction.","volume":"104","author":"Wang","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"R88-4-20210305","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1053\/j.gastro.2010.06.067","article-title":"Histamine2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel.","volume":"139","author":"Wu","year":"2010","journal-title":"Gastroenterology"},{"key":"R89-4-20210305","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/S0828-282X(10)70008-8","article-title":"The impact of treatment with omeprazole on the effectiveness of clopidogrel drug therapy during the first year after successful coronary stenting.","volume":"26","author":"Zairis","year":"2010","journal-title":"Can J Cardiol"},{"key":"R90-4-20210305","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1111\/j.1538-7836.2010.04049.x","article-title":"Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis.","volume":"8","author":"Siller-Matula","year":"2010","journal-title":"J Thromb Haemost"},{"key":"R92-4-20210305","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/j.1365-2036.2010.04247.x","article-title":"Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel.","volume":"31","author":"Kwok","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"R94-4-20210305","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1592\/phco.30.3.275","article-title":"Drug interaction between clopidogrel and proton pump inhibitors.","volume":"30","author":"Liu","year":"2010","journal-title":"Pharmacotherapy"},{"key":"R95-4-20210305","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1741-7015-8-81","article-title":"The potential interaction between clopidogrel and proton pump inhibitors: a systematic review.","volume":"8","author":"de Aquino","year":"2010","journal-title":"BMC Med"},{"key":"R96-4-20210305","doi-asserted-by":"crossref","first-page":"183","DOI":"10.4103\/0253-7613.77360","article-title":"Impact of proton pump inhibitors on efficacy of clopidogrel: Review of evidence.","volume":"43","author":"Mistry","year":"2011","journal-title":"Indian J Pharmacol"},{"key":"R97-4-20210305","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/11584750-000000000-00000","article-title":"Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis.","volume":"34","author":"Kwok","year":"2011","journal-title":"Drug Saf"},{"key":"R98-4-20210305","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0002-9343(80)90363-0","article-title":"The problem of protopathic bias in case-control studies.","volume":"68","author":"Horwitz","year":"1980","journal-title":"Am J Med"},{"key":"R99-4-20210305","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1161\/CIRCULATIONAHA.106.686048","article-title":"Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment.","volume":"116","author":"Airoldi","year":"2007","journal-title":"Circulation"},{"key":"R106-4-20210305","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0140-6736(09)61246-0","article-title":"Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial.","volume":"374","author":"Taha","year":"2009","journal-title":"Lancet"},{"key":"R107-4-20210305","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s00223-006-0021-7","article-title":"Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture.","volume":"79","author":"Vestergaard","year":"2006","journal-title":"Calcif Tissue Int"},{"key":"R108-4-20210305","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.296.24.2947","article-title":"Long-term proton pump inhibitor therapy and risk of hip fracture.","volume":"296","author":"Yang","year":"2006","journal-title":"JAMA"},{"key":"R109-4-20210305","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00223-008-9188-4","article-title":"Increase in vertebral fracture risk in postmenopausal women using omeprazole.","volume":"84","author":"Roux","year":"2009","journal-title":"Calcif Tissue Int"},{"key":"R110-4-20210305","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1053\/j.gastro.2010.03.055","article-title":"Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients.","volume":"139","author":"Corley","year":"2010","journal-title":"Gastroenterology"},{"key":"R111-4-20210305","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1592\/phco.28.8.951","article-title":"Proton pump inhibitor use and risk of hip fractures in patients without major risk factors.","volume":"28","author":"Kaye","year":"2008","journal-title":"Pharmacotherapy"},{"key":"R112-4-20210305","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1503\/cmaj.071330","article-title":"Use of proton pump inhibitors and risk of osteoporosis-related fractures.","volume":"179","author":"Targownik","year":"2008","journal-title":"CMAJ"},{"key":"R113-4-20210305","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1053\/j.gastro.2009.11.014","article-title":"Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss.","volume":"138","author":"Targownik","year":"2010","journal-title":"Gastroenterology"},{"key":"R114-4-20210305","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00223-008-9170-1","article-title":"Acid-suppressive medications and risk of bone loss and fracture in older adults.","volume":"83","author":"Yu","year":"2008","journal-title":"Calcif Tissue Int"},{"key":"R115-4-20210305","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s00198-009-0891-4","article-title":"Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates.","volume":"20","author":"de Vries","year":"2009","journal-title":"Osteoporos Int"},{"key":"R116-4-20210305","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/archinternmed.2010.94","article-title":"Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Womens Health Initiative.","volume":"170","author":"Gray","year":"2010","journal-title":"Arch Intern Med"},{"key":"R117-4-20210305","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s00198-010-1337-8","article-title":"Use of proton pump inhibitors and risk of hipfemur fracture: a population-based case-control study.","volume":"22","author":"Pouwels","year":"2011","journal-title":"Osteoporos Int"},{"key":"R118-4-20210305","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/ajg.2011.113","article-title":"Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies.","volume":"106","author":"Ngamruengphong","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"R119-4-20210305","doi-asserted-by":"crossref","first-page":"917","DOI":"10.7326\/0003-4819-66-5-917","article-title":"The absorption of calcium carbonate.","volume":"66","author":"Ivanovich","year":"1967","journal-title":"Ann Intern Med"},{"key":"R120-4-20210305","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1056\/NEJM198507113130202","article-title":"Calcium absorption and achlorhydria.","volume":"313","author":"Recker","year":"1985","journal-title":"N Engl J Med"},{"key":"R122-4-20210305","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1080\/07315724.1995.10718522","article-title":"Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans.","volume":"14","author":"Serfaty-Lacrosniere","year":"1995","journal-title":"J Am Coll Nutr"},{"key":"R124-4-20210305","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1002\/jbmr.108","article-title":"Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial.","volume":"25","author":"Wright","year":"2010","journal-title":"J Bone Miner Res"},{"key":"R125-4-20210305","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1172\/JCI111254","article-title":"An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium.","volume":"73","author":"Bo-Linn","year":"1984","journal-title":"J Clin Invest"},{"key":"R126-4-20210305","first-page":"1376","article-title":"Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects.","volume":"10","author":"Graziani","year":"1995","journal-title":"Nephrol Dial Transplant"},{"key":"R127-4-20210305","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.amjmed.2005.02.007","article-title":"Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial.","volume":"118","author":"OConnell","year":"2005","journal-title":"Am J Med"},{"key":"R128-4-20210305","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.abb.2008.03.025","article-title":"Function, structure and regulation of the vacuolar (H)-ATPases.","volume":"476","author":"Jefferies","year":"2008","journal-title":"Arch Biochem Biophys"},{"key":"R129-4-20210305","first-page":"222","article-title":"Osteopetrosis.","volume":"32","author":"Kocher","year":"2003","journal-title":"Am J Orthop (Belle Mead NJ)"},{"key":"R131-4-20210305","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.bone.2010.12.033","article-title":"Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features.","volume":"48","author":"Giusti","year":"2011","journal-title":"Bone"},{"key":"R132-4-20210305","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3109\/17453674.2011.581267","article-title":"Bisphosphonate-associated atypical fracture of the femur: Spontaneous healing with drug holiday and re-appearance after resumed drug therapy with bilateral simultaneous displaced fracturesa case report.","volume":"82","author":"Pauh","year":"2011","journal-title":"Acta Orthop"},{"key":"R133-4-20210305","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3109\/17453674.2010.539500","article-title":"Diaphyseal femoral fatigue fracture associated with bisphosphonate therapy3 more cases.","volume":"82","author":"Osugi","year":"2011","journal-title":"Acta Orthop"},{"key":"R134-4-20210305","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3928\/01477447-20100526-10","article-title":"Atraumatic bilateral femur fracture in long-term bisphosphonate use.","volume":"33","author":"Ott","year":"2010","journal-title":"Orthopedics"},{"key":"R136-4-20210305","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMc066308","article-title":"Proton-pump inhibitors and hypomagnesemic hypoparathyroidism.","volume":"355","author":"Epstein","year":"2006","journal-title":"N Engl J Med"},{"key":"R137-4-20210305","doi-asserted-by":"crossref","first-page":"755","DOI":"10.7326\/0003-4819-151-10-200911170-00016","article-title":"Hypomagnesemia induced by several proton-pump inhibitors.","volume":"151","author":"Broeren","year":"2009","journal-title":"Ann Intern Med"},{"key":"R138-4-20210305","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1365-2265.2008.03194.x","article-title":"Severe hypomagnesaemia in long-term users of proton-pump inhibitors.","volume":"69","author":"Cundy","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R139-4-20210305","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1053\/j.ajkd.2009.11.019","article-title":"A case series of proton pump inhibitor-induced hypomagnesemia.","volume":"56","author":"Hoorn","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"R140-4-20210305","first-page":"169","article-title":"Hypomagnesaemia due to use of proton pump inhibitors: a review.","volume":"67","author":"Kuipers","year":"2009","journal-title":"Neth J Med"},{"key":"R141-4-20210305","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/qjmed\/hcq021","article-title":"Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series.","volume":"103","author":"Mackay","year":"2010","journal-title":"QJM"},{"key":"R142-4-20210305","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1111\/j.1572-0241.2007.01509.x","article-title":"Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion.","volume":"102","author":"Metz","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"R143-4-20210305","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1053\/j.ajkd.2010.03.013","article-title":"Severe hypomagnesemia during long-term treatment with a proton pump inhibitor.","volume":"56","author":"Regolisti","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"R144-4-20210305","doi-asserted-by":"crossref","first-page":"a425","DOI":"10.1136\/bmj.39505.738981.BE","article-title":"Omeprazole and refractory hypomagnesaemia.","volume":"337","author":"Shabajee","year":"2008","journal-title":"BMJ"},{"key":"R146-4-20210305","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/MOG.0b013e3282f37b59","article-title":"Recent developments in intestinal magnesium absorption.","volume":"24","author":"Quamme","year":"2008","journal-title":"Curr Opin Gastroenterol"},{"key":"R147-4-20210305","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ng889","article-title":"Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family.","volume":"31","author":"Schlingmann","year":"2002","journal-title":"Nat Genet"},{"key":"R148-4-20210305","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1080\/07315724.1995.10718522","article-title":"Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans.","volume":"14","author":"Serfaty-Lacrosniere","year":"1995","journal-title":"J Am Coll Nutr"},{"key":"R149-4-20210305","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/MOG.0b013e32833ff5d6","article-title":"Proton pump inhibitors and severe hypomagnesaemia.","volume":"27","author":"Cundy","year":"2011","journal-title":"Curr Opin Gastroenterol"}],"container-title":["Journal of Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCG.0b013e3182333820","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T08:33:30Z","timestamp":1713342810000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004836-201202000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":125,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/mcg.0b013e3182333820","relation":{},"ISSN":["0192-0790"],"issn-type":[{"value":"0192-0790","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}